Logo

Merck Reports US FDA’s Acceptance of sBLA for Keytruda Plus Chemotherapy with Priority Review for Endometrial Carcinoma

Share this
Merck

Merck Reports US FDA’s Acceptance of sBLA for Keytruda Plus Chemotherapy with Priority Review for Endometrial Carcinoma

Shots:

  • Merck’s sBLA for Keytruda, combined with SoC CT (carboplatin and paclitaxel) and as monotx. has been accepted by the US FDA and granted priority review for treating primary advanced/recurrent endometrial carcinoma with the decision expected on Jun 21, 2024
  • The sBLA was supported by the P-III (NRG-GY018) study investigating Keytruda + SoC CT (carboplatin and paclitaxel) vs PBO + CT for treating measurable stage III, IVA, IVB or recurrent endometrial cancer patients (n=816) in pMMR and dMMR cohorts
  • The results, highlighted in SGO’23 & the New England Journal of Medicine, showed reduction in the disease progression or death risk by 46% in patients with pMMR and by 70% in those with dMMR vs CT alone

Ref: Merck | Image: Merck

Related News:- Astellas Receives the MHLW’s Priority Review for the sNDA Submitted for Padcev and Keytruda as Combination Therapy to Treat Bladder Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions